BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• 

  FDA

  FDA Grants Evofem Biosciences’ Amphora Fast Track Designation

  The U.S. Food and Drug Administration (FDA) granted San Diego-based Evofem Biosciences Fast Track designation for Amphora vaginal gel to prevent urogenital chlamydia infection in women.

  February 21, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  11 Most Innovative Life Science Companies in the World

  Here is a look at the life science companies viewed as the most innovative in the world.

  February 21, 2018

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Could J&J’s Deal With Theravance Develop a Replacement for Remicade in IBD?

  Johnson & Johnson is hoping its $100 million deal with Theravance will serve as a replacement for Remicade which lost patent protection.

  February 21, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Leveraging IoT for Medical Device Software

  The RND Group recently implemented an Internet of Things (IoT) solution to manage a fleet of medical devices that perform diagnostic tests and push raw test data to the cloud.

  February 21, 2018

   · 

  4 min read
• 

  Deals

  Merck Drops $394 Million to Acquire Virus-Based Cancer Company Viralytics

  Merck is driving forward in its quest to develop a premier immuno-oncology pipeline by acquiring Australia-based Viralytics Limited and its oncolytic immunotherapy treatments.

  February 21, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  AbbVie’s Elagolix Hits Primary Endpoints for Uterine Fibroids

  AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.

  February 21, 2018

   · 

  3 min read
• 

  Biotech Bay

  ORIC Pharmaceuticals Snags $50 Million to Advance Lead Asset for Treatment-Resistant Cancers

  A new chief executive officer and a fresh infusion of $50 million in Series C funding has given Bay Area ORIC Pharmaceuticals a shot in the arm as it continues to push development of its lead asset for treatment-resistant cancers.

  February 21, 2018

   · 

  2 min read

   · 

  Alex Keown
• Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences

  Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to...

  February 21, 2018

   · 

  6 min read
• Business

  Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies

  Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialize Innovative Therapies

  February 21, 2018

   · 

  7 min read
• GB Sciences Receives Issuance of Its Cannabis Oil Production License

  GB Sciences enters full commercial operations with its cannabis oil production partners Cura Cannabis Solutions and RWH, a new venture co-founded by Deliciously Dee™

  February 21, 2018

   · 

  5 min read